Nearly Three Quarters of U.S. Travellers Support the Introduction of International Vaccine Passports, According to OAG Research
13.9.2021 16:00:00 EEST | Business Wire | Press release
Travellers are taking to the skies again, but the immediate future of air travel remains highly turbulent, according to OAG’s survey of 1,800-plus U.S. travellers in July and August. Domestic capacity in the U.S. is up 81% from June – August 2021, compared to the same period last year. The increase is being fuelled by strong consumer demand; 70% of consumers surveyed by OAG have booked flights for the future.
While travellers’ willingness to fly is increasing, the Delta variant, increased COVID transmission rates and vaccination preferences weigh heavily on the near and mid-term outlook. The large majority of consumers surveyed by OAG report being fully vaccinated. However, OAG found that only 15% of non-vaccinated individuals plan to get vaccinated before their next trip.
Many airlines and destinations are considering vaccine mandates to strengthen confidence and fight transmission. Sixty-eight percent of all survey respondents said they are interested in or want domestic vaccine passports, and 70% believe vaccine passports should be required for international travel. Alarmingly, of those that said they were not yet vaccinated, 56% said they still wouldn’t get vaccinated even if the airline, airport, or destination required it to travel.
“Vaccine mandates are a polarizing issue. Many airlines, governments and destinations are actively considering mandating vaccines to fly or enter, and the majority of travellers support the use of vaccine passports,” said John Grant, senior analyst at OAG. “While this may add fuel to hot fire, the ongoing strength and resilience of the entire travel market is directly linked to higher vaccination levels and lower transmission rates.”
Other takeaways from OAG’s research include:
- Continued COVID-19 concerns keep some travellers grounded. Of the 30% of respondents who haven’t booked flights yet, 40% are waiting for vaccination rates and regulations to improve and 30% are waiting for vaccine passports to be required.
- The business travel outlook remains cloudy. Only 62% of business travellers said their company is planning air travel in the next 12 months, while 38% said their company either has no plans (20%) or has not specified plans (18%).
- Holiday travel expected to bounce back. The 2021 holiday travel season projects to be a lot stronger than 2020. Of the 38% of travellers surveyed by OAG that said they typically fly for the holidays, only 40% of this group did so in 2020. This year, the percentage of that group who do intend to fly more than doubled (85%). Planned capacity for Thanksgiving week tells a similar story, currently with 47% more domestic seats booked than last year.
- Booking behaviour remains erratic. Nearly half of travellers surveyed are still booking on short notice (between two weeks to a month in advance), and half are booking between two-six-plus months out. Eighty-eight percent expect ticket prices to rise in the next 12 months.
For the full survey insights, view the report here, https://www.oag.com/us-traveler-survey. To learn more about OAG, visit https://www.oag.com/.
About OAG
OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. Headquartered in the UK, OAG has global operations in the USA, Singapore, Japan, Lithuania and China. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005014/en/
Contact information
Chrissy Azevedo
Corporate Ink for OAG
pressoffice@oag.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 04:00:00 EEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202628.5.2026 00:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said: “Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide ne
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
